ZYMEWORKS INC. Increase (Decrease) in Prepaid Expense and Other Assets
ZYMEWORKS INC. (ZYME) reported Increase (Decrease) in Prepaid Expense and Other Assets of $2.11 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-08-06
- ZYMEWORKS INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-06-30 was $383.00K.
- ZYMEWORKS INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-03-31 was $1.73M.
- ZYMEWORKS INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-12-31 was $5.12M.
- ZYMEWORKS INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-09-30 was -$3.27M, a 837.47% decline year-over-year.
- ZYMEWORKS INC. increase (decrease) in prepaid expense and other assets for fiscal 2025 was -$6.51M, a 361.51% decline from fiscal 2024.
- ZYMEWORKS INC. increase (decrease) in prepaid expense and other assets for fiscal 2024 was $2.49M.
- ZYMEWORKS INC. increase (decrease) in prepaid expense and other assets for fiscal 2023 was -$4.29M, a 308.60% decline from fiscal 2022.
- ZYMEWORKS INC. increase (decrease) in prepaid expense and other assets for fiscal 2022 was $2.06M, a 86.96% decline from fiscal 2021.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 3 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month | Increase (Decrease) in Prepaid Expense and Other Assets 9 month | Increase (Decrease) in Prepaid Expense and Other Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | $383.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $2.11M 10-Q · filed 2026-08-06 | $7.23M derived: sum of 3 quarters · filed 2026-08-06 | $3.96M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $1.73M 10-Q · filed 2026-05-07 | $6.85M derived: sum of 2 quarters · filed 2026-05-07 | $3.58M derived: sum of 3 quarters · filed 2026-05-07 | -$1.91M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $5.12M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $1.85M derived: sum of 2 quarters · filed 2026-03-02 | -$3.64M derived: sum of 3 quarters · filed 2026-08-06 | -$6.51M 10-K · filed 2026-03-02 |
| 2025-09-30 | -$3.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$8.76M derived: sum of 2 quarters · filed 2026-08-06 | -$11.63M 10-Q · filed 2025-11-06 | -$13.30M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$5.49M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$8.36M 10-Q · filed 2026-08-06 | -$10.03M derived: sum of 3 quarters · filed 2026-08-06 | -$9.59M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$2.87M 10-Q · filed 2026-05-07 | -$4.54M derived: sum of 2 quarters · filed 2026-05-07 | -$4.10M derived: sum of 3 quarters · filed 2026-05-07 | -$610.00K derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$1.67M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$1.23M derived: sum of 2 quarters · filed 2026-03-02 | $2.26M derived: sum of 3 quarters · filed 2026-03-02 | $2.49M 10-K · filed 2026-03-02 |
| 2024-09-30 | $443.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $3.93M derived: sum of 2 quarters · filed 2025-11-06 | $4.16M 10-Q · filed 2025-11-06 | $11.84M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-06-30 | $3.49M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $3.72M 10-Q · filed 2025-08-07 | $11.40M derived: sum of 3 quarters · filed 2026-03-02 | -$6.58M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-03-31 | $227.00K 10-Q · filed 2025-05-08 | $7.91M derived: sum of 2 quarters · filed 2026-03-02 | -$10.07M derived: sum of 3 quarters · filed 2026-03-02 | -$5.74M derived: sum of 4 quarters · filed 2026-03-02 |
| 2023-12-31 | $7.68M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$10.30M derived: sum of 2 quarters · filed 2026-03-02 | -$5.97M derived: sum of 3 quarters · filed 2026-03-02 | -$4.29M 10-K · filed 2026-03-02 |
| 2023-09-30 | -$17.98M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | -$13.65M derived: sum of 2 quarters · filed 2024-10-31 | -$11.98M 10-Q · filed 2024-10-31 | -$11.33M derived: sum of 4 quarters · filed 2025-03-05 |
| 2023-06-30 | $4.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $6.00M 10-Q · filed 2024-08-01 | $6.64M derived: sum of 3 quarters · filed 2025-03-05 | $7.93M derived: sum of 4 quarters · filed 2025-03-05 |
| 2023-03-31 | $1.67M 10-Q · filed 2024-05-02 | $2.31M derived: sum of 2 quarters · filed 2025-03-05 | $3.60M derived: sum of 3 quarters · filed 2025-03-05 | -$129.00K derived: sum of 4 quarters · filed 2025-03-05 |
| 2022-12-31 | $642.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-05 | $1.93M derived: sum of 2 quarters · filed 2025-03-05 | -$1.80M derived: sum of 3 quarters · filed 2025-03-05 | $2.06M 10-K · filed 2025-03-05 |
| 2022-09-30 | $1.29M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | -$2.44M derived: sum of 2 quarters · filed 2023-11-07 | $1.42M 10-Q · filed 2023-11-07 | $5.62M derived: sum of 4 quarters · filed 2024-03-06 |
| 2022-06-30 | -$3.73M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $127.00K 10-Q · filed 2023-08-10 | $4.33M derived: sum of 3 quarters · filed 2024-03-06 | |
| 2022-03-31 | $3.86M 10-Q · filed 2023-05-08 | $8.06M derived: sum of 2 quarters · filed 2024-03-06 | ||
| 2021-12-31 | $4.21M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-06 | $15.79M 10-K · filed 2024-03-06 | ||
| 2021-09-30 | $11.59M 10-Q · filed 2022-11-08 | |||
| 2020-12-31 | $3.52M 10-K · filed 2023-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |